Each year a specific amount from the central-government budget is allocated to taking on board new treatments and pharmaceuticals. This is then allocated according to the recommendations of a committee comprising representatives from the Ministry of Health, Ministry of Finance, the physicians and health funds as well as experts in health policy and public figures from outside the health system. The committee’s recommendations are based on a list of candidates for inclusion in the basket drawn up by the Ministry of Health in consultation with key players (notably the health funds, pharmaceutical companies and the IMA). Changes to the system in recent years include for instance the adoption of a multi-year allocation in 2008 (three years instead of one).